How does 1CG's PS Ratio compare to its peers?

1CG is expensive based on its Price-To-Sales Ratio (19.9x) compared to the peer average (13x).

How does 1CG's PS Ratio compare vs other companies in the European Biotechs Industry?

1CG is expensive based on its Price-To-Sales Ratio (19.9x) compared to the European Biotechs industry average (7.9x).

What is 1CG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 1CG's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 1CG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 1CG's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

CRISPR Therapeutics (BRSE:1CG) - Stock Price, News & Analysis

1CG Stock Overview

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. More details

1CG fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 54.35% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

CRISPR Therapeutics AG Competitors

Molecular Partners

SWX:MOLN

CHF 177.5m

Basilea Pharmaceutica

SWX:BSLN

CHF 491.5m

Kuros Biosciences

SWX:KURN

CHF 841.6m

Idorsia

SWX:IDIA

CHF 142.0m

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share Price	US$38.28
52 Week High	US$0
52 Week Low	US$0
Beta	1.66
11 Month Change	0%
3 Month Change	-10.62%
1 Year Change	-39.87%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-41.61%

Recent updates

Shareholder Returns

	1CG	CH Biotechs	CH Market
7D	0%	-17.7%	-1.7%
1Y	-39.9%	97.8%	5.0%

Return vs Industry: 1CG underperformed the Swiss Biotechs industry which returned 103% over the past year.

Return vs Market: 1CG underperformed the Swiss Market which returned 4.8% over the past year.

Price Volatility

Is 1CG's price volatile compared to industry and market?
1CG volatility
1CG Average Weekly Movement	n/a
Biotechs Industry Average Movement	12.7%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	6.5%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: 1CG's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine 1CG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	407	Sam Kulkarni	www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
1CG fundamental statistics
Market cap	CHF 3.56b
Earnings (TTM)	-CHF 211.60m
Revenue (TTM)	CHF 179.13m

19.9x

P/S Ratio

-16.8x

P/E Ratio

Is 1CG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1CG income statement (TTM)
Revenue	US$202.83m
Cost of Revenue	US$463.89m
Gross Profit	-US$261.06m
Other Expenses	-US$21.47m
Earnings	-US$239.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.81
Gross Margin	-128.71%
Net Profit Margin	-118.13%
Debt/Equity Ratio	0%

How did 1CG perform over the long term?

See historical performance and comparison

1CG Stock Overview

Rewards

Risk Analysis

CRISPR Therapeutics AG Competitors

SWX:MOLN

CHF 177.5m

SWX:BSLN

CHF 491.5m

SWX:KURN

CHF 841.6m

SWX:IDIA

CHF 142.0m

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Shareholder Returns

Price Volatility

About the Company

CRISPR Therapeutics AG Fundamentals Summary

19.9x

-16.8x

Earnings & Revenue